In vitro analysis, including 2D monolayer and 3D spheroid models, revealed the site-specific and controlled release of BTZ through ACE2 receptor-mediated endocytosis in subcellular endosomes, which inhibits the proteasome function of NSCLC cells (A549). The gene discussed is CASC3; the disease is non-small cell lung carcinoma.